Floatz logo

TEGAFUR

Pancreatic Neoplasm

Lee's Pharmaceutical LimitedSmall moleculePhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

382 Active assets in the Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

TEGAFUR is also rated in:

rectal cancerDormant
B
Indicative ·
59 / 100
View asset →
cervical intraepithelial neoplasia grade 2/3Dormant
B
Indicative ·
59 / 100
View asset →
Adjuvant ChemotherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →